Section Menu

Review of Current Studies for Researchers

With four Principal Investigators driving the HFH Sleep Research Center, all with unique research backgrounds and sleep research topics of interest, our team has a robust catalog of current studies with funding from the National Institutes of Health and the pharmaceutical industry. We have previously received funding from the Centers for Disease Control and Prevention and the American Academy for Sleep Medicine. Click on the study titles below to learn more about them.

NIH Funded Trials

Clinical Trials

Industry Supported Trials

COACH

Enhancing Digital CBT-I to Improve Adherence and Reduce Disparities

Principal Investigator: Philip Cheng, PhD

Despite the effectiveness of digital Cognitive Behavioral Therapy for insomnia (dCBT-I), there are significant disparities when it comes to treatment adherence and completion, particularly in vulnerable populations such as those with less access to socioeconomic resources. COACH is designed to identify an adaptive nurse coaching system of enhancing dCBT-I that fits patients' individual needs, increases treatment engagement, and closes that utilization gap. We have recently joined forces with Medicaid in an exciting partnership to research the effectiveness of this "enhanced dCBT-I."

For more information, email us at mtreger1@hfhs.org.

REACT

Sleep reactivity as a novel mechanism in Shift Work Disorder

Principal Investigator: Philip Cheng, PhD

Circadian misalignment is generally considered a core mechanism of Shift Work Disorder (SWD); however, our prior research suggests that there may be another key mechanism might be sleep reactivity. REACT is designed to establish sleep reactivity as an independent and clinically significant mechanism in SWD. If our hypotheses are supported, these results would generate more effective treatment plans that target multiple relevant mechanisms to improve sleep health and the lives of night shift workers.

For more information, email us at mtreger1@hfhs.org.

STRIDE

Sleep to reduce incident depression effectively

Principal Investigator: Christopher Drake, PhD

STRIDE is a sequential multiple assignment randomized trial to investigate the efficacy of a stepped-care model of insomnia treatment. Specifically, we are investigating the use of cognitive behavioral therapy for insomnia (CBT-I) to reduce symptoms of insomnia and prevent the onset of depression. Participants were enrolled in one of two internet treatment groups that focus on insomnia, and those in the CBT-I group used a digital program called Sleepio. Though participant enrollment has closed, STRIDE is still ongoing, and has informed the design of studies like COACH and PIVOT.

For more information, email us at ayu2@hfhs.org.

SAIL

A Pilot of a Personalized Circadian mHealth to Improve Sleep in Night Shift Workers

Principal Investigator: Philip Cheng, PhD

Almost all night shift nurses experience circadian misalignment, a phenomenon that occurs due to the mismatch between the night shift sleep-work schedule and the body-clock. This study tests the implementation of a personalized mobile health application (Arcashift) that uses data collection from a mobile phone and activity trackers to 1) assess individual shift worker’s body-clock timing, and 2) make personalized recommendations of light exposure schedules that are designed to align the body-clock with the night shift work schedule.

For more information, email us at jrusse12@hfhs.org.

REKINDLE: RE104-202-ADCO

REKINDLE is a double-blind placebo-controlled study aiming to evaluate the safety and efficacy of a synthetic psychedelic drug in alleviating the depressive symptoms of adjustment disorder in individuals who were recently diagnosed with a serious medical diagnosis (i.e. cancer, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), or idiopathic pulmonary fibrosis (IPF)).

For more information, please email mbross1@hfhs.org.

RECLAIM: RE104-203-GAD

Generalized anxiety disorder affects approximately 2.7% of adults in the United States in any given year. RECLAIM is a double-blind placebo-controlled study aiming to evaluate the safety and efficacy of a single-dose synthetic psychedelic drug in alleviating anxiety symptoms.

For more information, please email mbross1@hfhs.org.

Cookie Consent

We use cookies to improve your website experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement  to learn what information we collect and how we use it.

Accept All
Dismiss